AEZS 112

Drug Profile

AEZS 112

Alternative Names: AEZS-112; ZEN-012

Latest Information Update: 22 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AEterna Zentaris Inc
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Tubulin polymerisation inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Lymphoma; Solid tumours

Most Recent Events

  • 23 Sep 2009 Final safety and efficacy data from a phase I trial in Solid tumours and lymphoma released by AEterna Zentaris
  • 22 Apr 2009 Interim adverse events, pharmacokinetics and efficacy data from a phase I trial in solid tumours and lymphoma presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009) ,
  • 10 Jan 2007 Phase-I clinical trials in Lymphoma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top